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In Brief
The V3 loop and the CD4 binding site of
the HIV-1 envelope are frequently
targeted by neutralizing antibodies.
Moody et al. show that V3 and CD4bs
antibodies from chronically infected
individuals, which display limited
heterologous neutralization breadth, can
inhibit autologous HIV-1. Such antibodies
can select neutralization-resistant
autologous viruses.Accession NumbersKT220752
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The third variable (V3) loop and the CD4 binding site
(CD4bs) of the HIV-1 envelope are frequently tar-
geted by neutralizing antibodies (nAbs) in infected
individuals. In chronic infection, HIV-1 escape mu-
tants repopulate the plasma, and V3 and CD4bs
nAbs emerge that can neutralize heterologous
tier 1 easy-to-neutralize but not tier 2 difficult-to-
neutralize HIV-1 isolates. However, neutralization
sensitivity of autologous plasma viruses to this
type of nAb response has not been studied.
We describe the development and evolution in vivo
of antibodies distinguished by their target specificity
for V3 and CD4bs epitopes on autologous tier 2
viruses but not on heterologous tier 2 viruses. A sur-
prisingly high fraction of autologous circulating
viruses was sensitive to these antibodies. These
findings demonstrate a role for V3 and CD4bs anti-354 Cell Host & Microbe 18, 354–362, September 9, 2015 ª2015 Elsbodies in constraining the native envelope trimer
in vivo to a neutralization-resistant phenotype, ex-
plaining why HIV-1 transmission generally occurs
by tier 2 neutralization-resistant viruses.
INTRODUCTION
Inducing antibodies with neutralization breadth is a primary goal
of HIV-1 vaccine development (Mascola and Haynes, 2013).
Broadly neutralizing antibodies (bnAbs) can block infection in
macaques; however, current HIV-1 envelope (Env) immunogens
induce only nAbs that inhibit easy-to-neutralize (tier 1) HIV-1
strains. In contrast, bnAbs that potently neutralize difficult-to-
neutralize (tier 2)HIV-1strainsassociatedwithHIV-1 transmission
are not inducedby current vaccines (Mascola andHaynes, 2013).
Initial autologous nAbs in HIV-1-infected subjects are
restricted to neutralizing the infecting transmitted/founder
(T/F) virus (Derdeyn et al., 2014). Epitopes frequently targeted
by these nAbs are the third constant region-variable loop 4evier Inc.
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Figure 1. Clonal Lineages Derived from
CH0457
(A) The kite-shaped gate shows a diagonal of
gp120ConC core+/+memory B cells that were sorted
as single cells. Antigen-specific cell frequency was
similar in both samples; week 8 is shown.
(B) IgG1 gp120 V3 mAbs (CH14, CH48) were not
related to other isolated mAbs. Lineage CH13 had
six IgG1 mAbs (VH1 69/JH3; VK1 39/JK4); mean
heavy chain (HC) mutation frequency = 9.8%.
Lineage CH27 had three mAbs: two IgA2 (CH27,
CH28) and a IgG1 (CH44) (VH3 66/JH2; VK3
20/JK1); mean HC mutation frequency = 15.7%.
Trees were plotted on the same scale.
(C) Residues critical for lineage CH13 and lineage
CH27mAb binding (Tables S2 and S3) highlighted in
the structure of gp120C.YU2 (CD4 light gray, gp120
light blue, mAb 17b not shown). Mapped residues
are largely located within the CD4-gp120 contact
surface. V1/V2 is not shown because it was absent
in the crystal structure.
(D) CH14 and CH48 binding to peptides reflective of
multiple HIV-1 clades. Both bound V3 loop peptides
(residues 301–325) across multiple clades; no
binding was found for other epitopes.(C3-V4) domain, the base of the third variable (V3) loop, the
first and second variable loop (V1V2) regions, and the CD4
binding site (CD4bs). In chronic HIV-1 infection, virus escape
mutants repopulate the plasma virus pool, and neutralization
breadth accrues to varying degrees in different persons
(Hraber et al., 2014). V3 and CD4bs nAbs arise that can
neutralize heterologous tier 1 but not tier 2 HIV-1 isolates
(Montefiori et al., 2012; Moore et al., 1994), although heterol-
ogous tier 2 neutralization is seen with some CD4bs (Scheid
et al., 2011) and V3 (Gorny et al., 2009; Hioe et al., 2010) an-
tibodies. However, neutralization sensitivity of autologous
plasma viruses to this type of V3 and CD4bs nAb response
has not been studied. Here, we isolated from two chronically
HIV-1-infected persons V3 and CD4bs neutralizing mono-
clonal antibodies (mAbs) with breadth for tier 1 but not tier 2
heterologous viruses and tested their ability to neutralize a
large panel of autologous viruses. We also isolated CD4bs
bnAbs with tier 2 breadth and tested their ability to neutralize
the same panel of autologous viruses that includes escape
mutants. Surprisingly, we found a group of V3 and CD4bs
tier 1 heterologous virus-nAbs that neutralized a proportion
of autologous tier 2 viruses. These nAbs differ from more
common tier 1 virus-reactive antibodies that neutralize autolo-
gous and heterologous tier 1 viruses exclusively. We suggestCell Host & Microbe 18, 354–362,that the autologous tier 2-reactive V3
and CD4bs nAbs described here play
a previously underappreciated role in
neutralizing autologous tier 1 and tier 2
primary viruses, thus continuously select-
ing autologous viruses for neutraliza-
tion-resistance. This additional level of
immune surveillance against HIV-1 Env
trimers with relaxed or ‘‘open’’ conforma-
tions likely contributes to the finding thatT/F viruses exhibit tier 2 (or greater) neutralization resistance, a
finding relevant to HIV-1 vaccine research.
RESULTS
Restricted or Broad nAbs from Chronically Infected
Persons
We isolated two B cell clonal lineages (CH13, CH27) and single
mAbs from chronically clade C HIV-1-infected African person
CH0457 known to have plasma broad neutralizing activity
(Tomaras et al., 2011), using antigen-specific memory B cell
sorting of peripheral blood mononuclear cells (PBMCs) (Figures
1A and 1B; Table S1). Epitope mapping with virus mutants
showed CH13 lineage mAbs bound to the CD4bs (Figure 1C;
Tables S2 and S3); lineage members neutralized 8/8 tier 1
but 0/40 tier 2 heterologous HIV-1 Env pseudoviruses (Figure 2).
Two other mAbs, CH14 and CH48, were not clonally related,
and both mapped to the HIV-1 Env V3 loop (Figure 1D; Table
S4). Like CD4bs clonal lineage CH13, V3 mAbs CH14 and
CH48 neutralized tier 1 but not tier 2 heterologous HIV-1 strains
(Figure 2).
The second mAb clonal lineage, termed CH27 (Figure 1B),
had one IgG1 (CH44) and two IgA2 (CH27, CH28) members
(Table S1). All lineage members (CH27, CH28, CH44)September 9, 2015 ª2015 Elsevier Inc. 355
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Figure 3. Heterologous Neutralization by
mAbs from CH505
V3 mAbs DH151 and DH228 from CH505 tested
against heterologous HIV isolates. Tier 1 isolates
(2/4) were neutralized; 0/16 tier 2 isolates were
neutralized.neutralized 40% (range 25%–48%) of 40 tier 2 heterologous
HIV-1 strains (Figure 2) and preferentially neutralized tier 2
but not tier 1 heterologous viruses. HJ16 is a CD4bs bnAb iso-
lated from another infected person, and like the CH27 lineage
mAbs, HJ16 neutralizes multiple tier 2 but not tier 1 viruses.
Mutation of Env at N276 conferred resistance to HJ16
(Balla-Jhagjhoorsingh et al., 2013), and CH27 lineage mAbs
were sensitive to mutations at N276 and T278 (Table S3).
CH27, CH44, and HJ16 cross-blocked each other for Env
binding (Figure S1), showing that CH27 lineage bnAbs were
similar to HJ16 (Figure 2). Serum from chronically infected
person CH0457 taken at weeks 8 and 96 of the study were
tested against the same panel of heterologous viruses (Fig-
ure 2). Neutralization titers and breadth were similar at the
two chronic infection time points (R2 = 0.95, Pearson’s corre-
lation p < 2.2 3 1016). The neutralization pattern of CH27
lineage bnAbs accounted for part of serum breadth, butFigure 2. Heterologous Neutralization by mAbs from CH0457
Neutralization ofmAbs against tier 1 and tier 2 viruses from diverse clades shown in colored boxes (EC50). Con
96 are shown; serum is shown as reciprocal ED50. Lineage CH13 mAbs and non-lineage mAbs (CH14,
neutralized one tier 2 virus (C.246F_C1G). Lineage CH27 neutralized one tier 1 virus but 23/40 (58%) tier 2 virus
all tier 1 viruses at > 1:20 and 37/40 (93%) and 31/40 (78%) of tier 2 viruses, respectively.
Cell Host & Microbe 18, 354–362, Ssome viruses in the panel were neutral-
ized by serum and not the isolated
mAbs (e.g., C.Ce2010_F5 in Figure 2),
indicating that the isolated mAbs only
partially recapitulated serum neutraliza-
tion and that other bnAbs might have
been present in this person.
From a second person, CH505, previ-
ously described to have a CD4bs bnAb
lineage (represented byCH103 in Figure 3)
(Liao et al., 2013), we isolated by limiting
dilution memory B cell culture two V3
nAbs (DH151, DH228; Table S4) from
176 and 41 weeks after transmission,
respectively (Figure 3). DH151 and
DH228 neutralization was similarly
restricted to a subset of tier 1 heterolo-
gous viruses, and they neutralized 0/16
tier 2 heterologous viruses (Figure 3).
Virus Evolution in Chronically
Infected Person CH0457
We amplified 209 CH0457 env gene se-
quences by single genome amplification
(SGA) from ten time points over 2 years
during chronic infection (weeks of chronic
infection study 0, 2, 4, 8, 12, 16, 24, 48, 72,96 post-enrollment). A mean of 21 (range 12–35) SGA env se-
quences were analyzed for each time point. Phylogenetic anal-
ysis showed that Env sequences continuously evolved over
time; Envs from weeks 48, 72, and 96 were more divergent
versus earlier Envs (week 0–16) (Figure S2). Furthermore,
within-subject phylogeny maintained a persistent minority clade
that represented a small fraction (mean 14%) of Envs sampled at
any given time point (Figure 4; Figure S2) throughout the study.
Consensus of this clade differed at 85/888 (9.6%) aligned Env
amino acid positions from the main clade consensus. Analysis
of sequences from CH0457 relative to the database indicated
that despite the genetic distance, sequences from this minor
persistant clade were more closely related to other sequences
from CH0457 than to heterologous strains (not shown); we
further validated the relationship of the two clades by identifying
transition states between the two clades in archival DNA proviral
sequences (Figure S2). The minor clade contained memberstrol (HIVIG-C) and CH0457 serum fromweeks 8 and
CH48) potently neutralized tier 1 viruses but only
es. CH0457 serum fromweeks 8 and 96 neutralized
eptember 9, 2015 ª2015 Elsevier Inc. 357
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(A–C) Neutralization heat map of autologous serum andmAbs shown. Each row in the neutralization panel (A) of 84 CH0457 pseudoviruses and phylogeny tree (B)
is a distinct Env isolate spanning week 0 (enrollment; red) to week 96 after enrollment (purple). PBMC provirus sequences are gray. Autologous serum
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from many sampling time points across 2 years of infection; a
Slatkin-Madison test strongly supported compartmentalization
(p = 0.0001). Interestingly, these two divergent virus populations
persisted during the 96 weeks of sampling without apparent
recombination between the two clades, although some recombi-
nation within the lineages was evident.
Neutralization of Autologous Viruses by bnAbs and
Tier 1 Virus-nAbs
We made 84 pseudoviruses from these env sequences (Fig-
ure 4B; mean 8 per time point; range 7–11) to assay against
CH0457 serum (Figure 4A). Later serum time points (weeks 72–
96) potently neutralized early viruses (weeks 0–48) but not later
viruses, indicating that autologous nAbs were continuously eli-
cited during chronic infection in CH0457 (Figures 4A and 4B).
Assay of CH27 CD4bs lineage bnAbs against these 84 autolo-
gous pseudoviruses showed that five wereweakly neutralized by
1 of 3 lineage CH27 bnAbs (range 32–50 mg/ml), while 79 (94%)
resisted CH27 lineage bnAbs (Figure 4A; Figure S3A). This sug-
gested that the autologous virus pool in CH0457 had already
escaped from pressure exerted by the CH27 lineage bnAbs,
with viral escape occurring during chronic infection prior to study
enrollment.
To seek definitive evidence of selection by CH27 lineage
bnAbs, we amplified proviral env genes archived in PBMCs
from the earliest time point (week 0) in this study. Like plasma-
derived Env pseudoviruses, most PBMC-derived Env pseudovi-
ruses resisted lineageCH27bnAbs (Figures4Aand4B).However,
two cell-derived Env pseudoviruses (w0.35c, w0.29c) were highly
sensitive to CH27 lineage bnAbs, thus documenting CH27 bnAb
lineage-mediated escape (Figure 4A; Figure S3B). Remarkably,
both sensitive viruses were members of the persistent minority
clade (Figure 4B; Figure S2).
We tested CH0457 tier 1 virus-nAbs (5 CH13 lineage CD4bs
mAbs, 2 V3 mAbs CH14, CH48) against autologous HIV-1 pseu-
doviruses and found that the V3 and CD4bs mAbs neutralized
autologous viruses throughout the 2-year study period, including
PBMC-archived viruses (Figures 4A and 4B; Figures S3A and
S3B). Remarkably, the CD4bs lineage CH13 tier 1-nAbs neutral-
ized 52/84 (62%) and 11/34 (32%) of autologous plasma and
PBMC viruses, respectively, while V3 tier 1 virus-nAbs (CH14,
CH48) neutralized 67/84 (80%) plasma and 28/34 (82%)
PBMC viruses. Tier 1 virus-nAb potency ranged from 0.06 to
50 mg/ml, with potency of% 2 mg/ml for 21/257 (8%) autologous
virus neutralization assays. Sensitivity to CH13 lineage and V3
mAbs peaked at week 24 after enrollment; by week 48 most vi-
ruses resisted the V3 mAbs (Figure 4A; Figure S3A), suggesting
escape from these nAbs. Across all time points, 32/84 (38%)
autologous pseudoviruses resisted the CD4bs nAbs while 17/
84 (20%) resisted the V3 mAbs. CH0457 Env sequences did
not show accumulation of Env mutations at nAb contact sites
suggested by epitope mapping (Tables S2–S4). Other studies
have shown that V3 in chronic infection either did not change
(Nyambi et al., 2008) or accumulated sensitivity mutations overneutralization (reciprocal dilution) and isolated mAbs (mg/ml) are shown for (A) line
and CH48 (tier 1 V3) and (C) CH505 mAbs DH151 and DH228 (tier 1 V3) and line
(D) CH505 Env phylogeny spans transmission (week 0, red) through week 100
mAbs.
Cell Host &time (Haldar et al., 2011), and V3 epitopes otherwise sensitive
to mAbs can be occluded by other regions of Env (Upadhyay
et al., 2014). Thus, both common CD4bs and V3 tier 1 virus-
nAbs can select virus escapemutants that shape the autologous
virus reservoir toward neutralization resistance.
Among viruses sampled between weeks 48 and 96, only three
were moderately sensitive to the tier 1-virus nAb CD4bs CH13
lineage (w48.20, w72.2, w72.18), with the rest weakly sensitive
or completely resistant. These CH0457 viruses were all within
the persistent minor clade (3/10 in minor clade versus 0/17 in
dominant clade; Fisher’s exact test p = 0.04). That for both
CD4bs lineages the sensitive viruses persisted longest in the
minor but not the dominant virus clade raises the possibility
that viruses in the minor clade may be emerging from an immu-
nologically protected site (e.g., brain or CD4 T cell latent pool)
where antibody pressure would be limited.
To determine if autologous virus neutralization by autologous
tier 1 virus nAbs was unique to CH0457, we studied two V3 tier
1 virus-nAbs (DH151, DH228; Table S4) isolated from a second
HIV-1-infected African person, CH505, 176 and 41 weeks after
transmission, respectively; CH505 also developed a CD4bs
clonal lineage (termed CH103) at 136 weeks after transmission
(Liao et al., 2013). CH505 was studied earlier during infection
versus CH0457; thus Env selection by bnAbs was still ongoing,
and many autologous Env pseudoviruses were only partially
resistant to the CH103 bnAb lineage (Figure S3C) (Gao et al.,
2014). Both CH505 V3 mAbs (CH151, CH228) neutralized
some heterologous tier 1 viruses but 0/16 tier 2 viruses (Figure 3).
However, V3 mAbs DH151 and DH228 neutralized 45/96
(47%, IC50 range 0.03–50 mg/ml) autologous CH505 viruses (Fig-
ure 4C; Figure S3C) and potently neutralized 7/96 (7.3%) viruses
at % 2 mg/ml. Interestingly, the T/F virus from CH505 resisted
both V3 nAbs but became sensitive by week 14 (Figures 4C
and 4D; Figure S3C), showing that some CH505 autologous vi-
ruses had Env V3 epitope exposure by week 14 after infection.
As in CH0457, we did not find Env mutations accumulating at
binding sites of these mAbs, but we did find autologous
CH505 viruses sensitive to V3 mAbs at all time points studied.
Thus, CH505 V3 mAbs DH151 and DH228 had no neutralizing
activity against heterologous tier 2 viruses but neutralized autol-
ogous CH505 viruses, indicating that this phenomenon was not
limited to the chronically HIV-1-infected person CH0457.
Autologous Virus Neutralization Sensitivity
To assess autologous virus susceptibility to heterologous nAbs,
we assayed CH0457 pseudoviruses and found 73/84 (87%) sen-
sitive to heterologous VRC01-like CD4bs bnAb CH31 (Wu et al.,
2011) and 55/62 (89%) sensitive to loop binding CD4bs bnAb
CH106 (Liao et al., 2013) (Figure S3A). Glycan-dependent
bnAb HJ16 neutralized only 5/72 (7%) viruses, consistent
with escape from the HJ16-like lineage CH27 nAbs (Figure S1;
Table S3).
To assess overall neutralization sensitivity, we tested 84
CH0457 Env pseudoviruses against pooled serum (HIVIG-C)age CH13 mAbs (tier 1 CD4bs), lineage CH27 mAbs (tier 2 CD4bs), and CH14
age CH103 (tier 2 CD4bs).
(purple). A high fraction of circulating viruses were sensitive to autologous
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and a subset against well-characterized HIV-1 patient sera (Sea-
man et al., 2010) (Figure S3D). The data suggested that CH0457
viruses sensitive to autologous tier 1 virus-nAbs (CH13 lineage,
CH14, CH48) had exposed V3 and CD4bs epitopes. We
analyzed a subset of Env pseudoviruses (ten sensitive/ten resis-
tant to autologous V3 and CD4bs tier 1 virus-nAbs) against
heterologous V3 and CD4bs mAbs known to not neutralize tier
2 viruses (Gorny et al., 2009; Montefiori et al., 2012) (Figure S4A).
Viruses sensitive to autologous tier 1 virus-nAbs were neutral-
ized by heterologous V3 and CD4bs nAbs, suggesting that V3
loop and CD4bs epitopes were trimer-surface exposed. Viruses
resistant to autologous nAbs also resisted heterologous nAbs
(Figure S4A). Sensitive viruses also had intermediate sensitivity
to a panel of neutralization typing sera (Figure S4A) consistent
with an intermediate (tier 1B) (Seaman et al., 2010) phenotype
(Figure S4B). Autologous viruses from CH505 tested with a
similar panel also showed predominant tier 1B neutralization
sensitivity (Figure S4C). These data showed that viruses from
chronic infection in African persons CH0457 and CH505 could
be neutralized by common V3 and CD4bs tier 1 virus-nAbs
that lacked tier 2 heterologous virus-neutralizing activity.
DISCUSSION
This study shows that a subset of common CD4bs and V3 anti-
bodies that neutralize tier 1 but not tier 2 heterologous viruses
have the capacity to neutralize autologous tier 2 viruses and
select for virus escape mutants. This observation is critical to
understanding how neutralization-resistant T/F viruses are
selected and how antibodies with tier 1 virus neutralization are
induced.
The initial autologous nAb response in acute HIV-1 infection is
specific for autologous virus with little or no tier 1 heterologous
breadth (Richman et al., 2003; Wei et al., 2003). In chronic infec-
tion breadth develops for heterologous tier 1 viruses, and viruses
can evolve in response to those nAbs (Haldar et al., 2011;
Kelly et al., 2005; Nyambi et al., 2008). However, autologous
virus-neutralizing mAbs isolated from HIV-1-infected people
have been strictly strain-specific with no detectable heterolo-
gous tier 1 or tier 2 HIV-1 neutralization (Derdeyn et al., 2014;
D.C.M., unpublished data). This study examines the dynamics
of this evolution by combining virus SGA with mAb isolation to
deconvolute the polyclonal antibody response in chronically
infected persons and demonstrate autologous nAbs with both
heterologous tier 1 and autologous tier 2 neutralizing activity.
We did not isolate all bnAbs or tier 1 nAbs from these persons.
However, we have shown ongoing and repeated emergence of
viruses sensitive to common CD4bs and V3 nAbs. In particular,
this class of nAbs does not appear to exert immune pressure
to the same degree as bnAbs, where we found evidence of com-
plete viral escape. It is possible that when autologous nAbs
begin to show heterologous tier 1 breadth, they may be devel-
oping into bnAbs, as occurred in the CH103 CD4bs lineage
(Liao et al., 2013), but at this time it is not known which antibody
lineages will mature to breadth.
We found autologous virus isolates were variably neutralized
by mAbs against the CD4bs and V3 loop (Figures S4A and
S4C). Recent work has shown that sensitive Envs spend more
time in conformationally open states that permit binding of anti-360 Cell Host & Microbe 18, 354–362, September 9, 2015 ª2015 Elsbodies without neutralization breadth (Munro et al., 2014). Our
data show that these sensitive viruses arise during chronic
HIV-1 infection and are likely the antigenic stimulus inducing
common antibodies that neutralize tier 1 heterologous viruses.
When we tested common CD4bs and V3 nAbs isolated from
the same subjects against their autologous viruses, the mAbs
neutralized both the sensitive viruses and a subset of autologous
isolates resistant to heterologous tier 1 virus-nAbs.We speculate
that neutralization of resistant viruses was possible because the
mAbs and viruses co-evolved in the same HIV-1-infected per-
sons and the antibodies gained the ability to bind autologous vi-
ruses. During HIV-1 infection, virus quasispecies evolve that
have different degrees of Env reactivity, including viruses with
high intrinsic reactivity (tier 1A) (Seaman et al., 2010) that are
more reactive with soluble CD4 and nAbs (Haim et al., 2011).
Our study indicates that autologous viruses with low Env reac-
tivity (tier 1B or tier 2) (Haim et al., 2011, 2013) can act as tem-
plates for antibody evolution, promoting development of nAbs
that bind and neutralize autologous virus Envswith low reactivity.
Such nAbs could broadly react with high-reactivity heterologous
tier 1A Envs but would be expected to bind poorly to low-reac-
tivity heterologous tier 2 Envs.
Autologous nAbs that arise in acute HIV-1 infection can exert
immune pressure and influence T/F virus evolution; the initial
autologous-specific nAb response appears within the first year
of infection and is associated with development of resistant vi-
ruses in virtually all infected people (Richman et al., 2003; Wei
et al., 2003). In addition, tier 1 virus nAbs of the type studied
here were shown to exert immune pressure in a humanized
mouse HIV-1 infection model (Klein et al., 2014). Our study is
unique in showing autologous tier 1 virus-nAb evolution over
time and the ability of those nAbs to combine with tier 2-virus-
nAbs to shape the neutralization sensistivity of the autologous
virus pool.
HIV-1 vaccine efficacy trials have not convincingly shown a
protective effect of vaccine-elicited tier 1 virus-nAbs, although
in secondary analyses, tier 1 nAbs correlated with decreased
risk of infection in VAX004 (Gilbert et al., 2005) and RV144
(Haynes et al., 2012). The only vaccine study to date that demon-
strated any protection (RV144) did not elicit tier 2 nAbs (Monte-
fiori et al., 2012). Secondary analyses of RV144 found that
V2-specific antibodies correlated with decreased transmission
risk (Gottardo et al., 2013; Zolla-Pazner et al., 2014), as did
antibody-dependent cellular cytotoxicity-mediating antibodies
(Haynes et al., 2012) and V3 antibodies (Gottardo et al., 2013)
in the context of other responses such as low Env-IgA (Haynes
et al., 2012). Recent studies of HIV-1 Env evolution over the
pandemic indicate that T/F viruses are evolving to bemore resis-
tant to bnAbs (Bouvin-Pley et al., 2014); thus a successful
vaccine may have to contend with an ever increasing degree
of resistance among HIV-1 strains. However, we found that
some tier 1 virus-nAbs can neutralize autologous tier 1B and
tier 2 HIV-1 Envs with which they co-evolved (Figure 4; Figures
S3A and S3C). If a vaccine elicited a sufficiently large and diverse
pool of tier 1 virus-nAbs, some degree of protection might be
possible.
Antibodies and autologous viruses are passed together in
bodily fluids associated with HIV-1 transmission. The present
study suggests that viruses with a more sensitive phenotypeevier Inc.
would be passed along with nAbs against those viruses, while
resistant viruses would be passed without nAbs against them.
This situation could cause a selection bias to favor infection by
viruses resistant to the autologous nAb response. Thus, the
observation that T/F viruses isolated from recently infected peo-
ple are of a more resistant phenotype could be partly explained
by the restricted tier 1 autologous virus-nAbs described here.
In addition, there is a setting where these kinds of nAbs could
be transferred to a susceptible host prior to virus exposure—
mother-to-child transmission (MTCT). Maternal IgG is actively
transferred to the fetus (Malek et al., 1996), and maternally
derived nAbs could plausibly prevent newborn infection. Thus,
V3- or CD4bs-directed nAbs of the type described here could
correlate with decreased transmission risk for MTCT. A recent
analysis has shown that a correlate of decreased MTCT trans-
mission risk was high plasma tier 1 virus-nAbs (Permar et al.,
2015). Boosting to achieve high levels of V3 and CD4bs autolo-
gous nAbs in pregnant women might be a way to reduce intra-
partum and peripartum HIV-1 transmission to infants that occurs
despite peripartum treatment with anti-retroviral drugs. Thus,
tier1 virus-nAbs can exert selection pressure on autologous virus
variants and determine intrinsic Env reactivity and sensitivity to
neutralization. Whether these common antibodies can be har-
nessed for protection in the setting of vaccination for MTCT
remains to be determined.
EXPERIMENTAL PROCEDURES
Ethics Statement
The present work was performed under a protocol approved by the Duke Uni-
versity Health System Institutional Review Board for Clinical Investigations.
The original studies fromwhich we obtained the clinical material herein studied
were approved by the Kilimanjaro Christian Medical Centre Research Ethics
Committee, the Tanzania National Institutes for Medical Research Ethics
Coordinating Committee, and the Institutional Review Boards of the London
School of Hygiene and Tropical Medicine and Duke University as well as by
the NIH Human Subject Review Committee.
Flow Cytometry, Memory B Cell Cultures, and mAb Isolation
The gp120ConC core protein was produced and used in flow cytometry on
PBMC from CH0457 using a two-color technique as described (Gray et al.,
2011). IgG+ memory cells from CH505 isolated from PBMC were cultured as
described (Gao et al., 2014). In both cases, Ig genes were amplified from
RNA from isolated cells, expression cassettes made, and mAbs expressed
as described (Gao et al., 2014).
Antibody Reactivity by Binding AntibodyMultiplex Assay, ELISA, and
Peptide Microarray
Expressed mAbs were assayed for reactivity to HIV-1 antigens using a stan-
dardized custom binding antibody multiplex assay (BAMA) using Luminex
(Tomaras et al., 2011). BAMA was performed with a panel of HIV-1 antigens
(gp140ConC, gp120ConC full length, gp140ConB, gp140ConG, gp140JR.FL),
mAbs with a blank-bead-subtracted value > 2,000 units, and > 1,000 3 mAb
IgG in mg/ml were evaluated further. Binding was confirmed on purified mAbs.
ELISA was performed as described (Tomaras et al., 2011); testing
was considered positive if the optical density at 405 nm was > 0.3 units
and > 4-fold over background. Epitope mapping by cross-clade peptide mi-
croarray was performed as described (Tomaras et al., 2011).
Amplification of Full-Length env Genes and Generation of
Pseudoviruses
After recovery of viral RNA or proviral DNA, 30 half genomes from plasma or
PBMCswere amplified by single genome amplication (SGA) as described (Sal-
azar-Gonzalez et al., 2009). Sequence contigs from each env SGA wereCell Host &assembled and edited using Sequencher 4.7 (Gene Codes). Pseudoviruses
were made by adding the CMV promoter to the 50 end of each SGA-amplified
env gene, then the pPCR product was cotransfected with the env-deficient
HIV-1 backbone pSG3Denv into 293T cells.
Neutralization Assay in TZM-bl Bells
Neutralizing antibody assays in TZM-bl cells were performed as described
(Montefiori et al., 2012). For some isolates, amino acid substitutions were
introduced by oligonucleotide-directed PCR mutagenesis. Neutralization of
pseudoviruses containing Env mutations was compared to wild-type pseu-
dovirus. A R 15-fold increase in IC50 from wild-type to mutant was consid-
ered positive.
Statistical Analysis
Statistical tests were performed in SAS, version 9.2 (SAS Institute) or in R,
version 2.15.2 (R Foundation for Statistical Computing). The statistical test is
noted when p values are presented.
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